We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App




Gene Expression Levels Measured in a Variety of Sample Types

By LabMedica International staff writers
Posted on 12 Nov 2009
Print article
A quantitative nuclease protection assay (qNPA) process will be applied microarrays to enable rapid and efficient measuring of gene expression levels in a variety of sample types.

Roche NimbleGen (Madison, WI, USA) and High Throughput Genomics (HTG; Tucson, AZ, USA), provider of the quantitative nuclease protection assay (qNPA), have entered into a supply agreement. Roche NimbleGen will provide HTG with high-density, multiplex DNA microarray slides for advanced gene-expression analysis. HTG will apply the company's quantitative nuclease-protection assay (qNPA) process to the microarrays to enable rapid and accurate measurements of the gene-expression levels in a variety of sample types.

The agreement enhances HTG's existing service capability offering with the ability to take a broader look at gene expression through the multiplex capability of the Roche NimbleGen microarrays. Sample preparation using qNPA technology allows for a much simpler, more cost-effective workflow versus traditional labeling methods, while the Roche NimbleGen multiplex technology offers a cost-effective high-density microarray providing in depth gene-expression information.

Gerd Maass, CEO of Roche NimbleGen said, "The partnership with HTG showcases the strengths of the two companies and the flexibility of the NimbleGen Arrays by pairing two innovative technologies to provide flexibility, time savings, and cost savings while offering the significant in depth genetic information that our high-density arrays provide."

Roche NimbleGen, Inc. is a manufacturer and supplier of a suite of DNA microarrays, consumables, instruments, and services. NimbleGen's Maskless Array Synthesis (MAS) technology uses digital light to produce high-density arrays of long oligo probes that provide information content and higher data quality necessary for studying the full diversity of genomic and epigenomic variation. Scientists can thus obtain a clearer understanding of genomic and epigenomic structure and function and how they impact medicine and biology.

Related Links:

Roche NimbleGen
High Throughput Genomics


New
Gold Member
Troponin T QC
Troponin T Quality Control
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Clinical Sample Concentrator
QIAamp DSP Virus Kit
New
Anti-Rubella IgG (Rubella IgG) Test
Rubella IgG AccuBind ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: The CELLSEARCH System is the first and only clinically validated, FDA-cleared system for identification, isolation, and enumeration of CTCs from a simple blood test (Photo courtesy of Menarini, Inc.)

Early Blood Test Predicts Survival in Patients with Metastatic Prostate Cancer

Before prostate cancer spreads, it can be effectively treated with surgery or radiation. However, once the cancer metastasizes and becomes incurable, systemic treatments are used to extend survival as... Read more

Hematology

view channel
Image: The discovery of a new blood group has solved a 50- year-old mystery (Photo courtesy of 123RF)

Newly Discovered Blood Group System to Help Identify and Treat Rare Patients

The AnWj blood group antigen, a surface marker discovered in 1972, has remained a mystery regarding its genetic origin—until now. The most common cause of being AnWj-negative is linked to hematological... Read more

Microbiology

view channel
Image: The Accelerate Arc System has been granted US FDA 510(k) clearance (Photo courtesy of Accelerate Diagnostics)

Automated Positive Blood Culture Sample Preparation Platform Designed to Fight Against Sepsis and AMR

Delayed administration of antibiotics to patients with bloodstream infections significantly increases the risk of morbidity and mortality. For optimal therapeutic outcomes, it is crucial to rapidly identify... Read more

Pathology

view channel
Image: Confocal- & laminar flow-based detection scheme of intact virus particles, one at a time (Photo courtesy of Paz Drori)

Breakthrough Virus Detection Technology Combines Confocal Fluorescence Microscopy with Microfluidic Laminar Flow

Current virus detection often relies on polymerase chain reaction (PCR), which, while highly accurate, can be slow, labor-intensive, and requires specialized lab equipment. Antigen-based tests provide... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.